Abstract: A gold nanoparticles conjugated with palmitoyl pentapeptide-4 (Palm-L-Lys-L-Thr-L-Thr-L-Lys-L-Ser-OH), compositions comprising them, use thereof in cosmetic treatments, as well as methods for obtaining said nanoparticles.

Abstract: Microcapsules contain a peptide (I), and peptides (II) or (III) coupled to a PLGA-containing polymeric shell. The microcapsules can be used to enhance skin penetration of active ingredients encapsulated therein, particularly in the field of cosmetics. A process can be used for preparing the microcapsules, and compositions can contain said microcapsules. The microcapsules can be used as a transdermal delivery system for the active ingredients encapsulated therein.

Abstract: The present invention relates to capsules comprising a peptide, lecithin, alginate, and divalent metal cation, compositions comprising said capsules, use thereof in cosmetic treatments, as well as methods of obtaining said capsules.

Abstract: The present invention relates to gold nanoparticles conjugated with palmitoyl pentapeptide-4 (Palm-L-Lys-L-Thr-L-Thr-L-Lys-L-Ser-OH), compositions comprising them, use thereof in cosmetic treatments, as well as methods for obtaining said nanoparticles.

Abstract: The present invention relates to targeted microcapsules comprising a skin aging compound to target fibroblast with a peptide, which is a FGF receptor agonist, wherein said peptide is coupled to the outer surface of the microcapsule. It also relates to the use of said microcapsules for the cosmetic prevention and/or cosmetic treatment of cutaneous effects of skin aging and to the cosmetic compositions comprising said microcapsules. The invention also relates to the FGF receptor agonist peptide coupled to the microcapsule.

Abstract: The present invention relates to a compound of formula (I) and to compositions comprising said compound, as well as the use of said compound and/or said compositions to prevent fungal and/or bacterial growth.

Abstract: The present invention relates to a compound of formula (I) and to compositions comprising said compound, as well as the use of said compound and/or said compositions to prevent fungal and/or bacterial growth.

Abstract: The present invention relates to targeted microcapsules or nanocapsules comprising a skin whitening compound to target melanocytes with a peptide, which is a MC1 receptor agonist, wherein said peptide is coupled to the outer surface of the microcapsule or nanocapsule. It also relates to the use of said microcapsules or nanocapsules for the cosmetic prevention and/or cosmetic treatment of cutaneous dark spots, and to the cosmetic compositions comprising said microcapsules or nanocapsules. The invention also relates to the MC1 receptor agonist peptide coupled to the microcapsule or nanocapsule. The invention also relates to a peptide for use as skin whitening compound.

Abstract: The present invention relates to compounds of formula (I), or pharmaceutically acceptable, stereoisomers, salts or solvates thereof to methods for their synthesis, and use in the treatment of pain.

Abstract: The present invention relates to new 3-substituted 6-nitrooxy-hexahydrofuro[3,2-b]furane derivatives possessing a superior pharmacological activity in thrombosis and in coronary ischemia models.

Abstract: The present invention relates to new 3-substituted 6-nitrooxy-hexahydrofuro[3,2-b]furane derivatives possessing a superior pharmacological activity in thrombosis and in coronary ischemia models.

Abstract: The present invention relates to stable S-nitrosothiols derivatives of formula (I) having vasodilating effect and which inhibit the aggregation of the platelets and which therefore are useful for the preparation of medicaments for treatment of NO related diseases. The invention also relates to a process for the synthesis of the compounds of formula (I).

Abstract: The present invention relates to new 3-substituted 6-nitrooxy-hexahydrofuro[3,2-b]furane derivatives possessing a superior pharmacological activity in thrombosis and in coronary ischemia models.

Abstract: The present invention relates to a method of treating an ophthalmological disease mediated by ocular hypertension or an intestinal disorder, comprising administering to a patient in need thereof a therapeutically effective amount of a compound of formula (I) or a tautomer, a pharmaceutically acceptable salt, a prodrug or a solvate thereof.

Abstract: The present invention relates to stable S-nitrosothiols derivatives of formula (I) having vasodilating effect and which inhibit the aggregation of the platelets and which therefore are useful for the preparation of medicaments for treatment of NO related diseases. The invention also relates to a process for the synthesis of the compounds of formula (I).

Abstract: The present invention refers to compounds of the general formula (I), to their possible pharmaceutically acceptable salts and tautomeric forms. The present invention also refers to a process for their production and to their use as antidiabetic and *hypoglycemic agents, alone or in combination with other antidiabetic agents, such as sulfonilureas or biguanides, as well as for the treatment of complications associated to the resistance to the insulin, such as hypertension, hyperuricemia or other cardiovascular, metabolic, endocrine conditions, or other conditions related with diabetes.

Abstract: New esters derived from (RR, SS)-3-(2-dimethylaminomethyl-1-hydroxycyclohexyl)phenyl 2-hydroxybenzoate, analog to Tramadol, a process for obtaining them and the use of these compounds for the production of a medicament with analgesic properties. These new products of general formula (I) exhibit an analgesic activity higher than that of tramadol.

Abstract: This invention discloses new fluorquinolonic derivatives of oxazolidinones of general formula (I) and processes for obtaining them, the corresponding pharmaceutical compositions and use thereof for manufacturing a medicament for the treatment of microbial infections. These new compounds are useful as antibacterial agents. Formula (I). Furthermore phenalen-type compounds according to general formula (II) are disclosed. Formula (II).

Abstract: This invention provides new benzothiophene derivatives of general formula (I) and a process for preparing them, the corresponding compositions and their use for manufacturing a medicine for the treatment of neurological disorders. These new compounds behave as serotonin reuptake inhibitors and show high affinity towards the 5-HT1A receptor.

Abstract: New esters derived from substituted phenyl-cyclohexyl compounds, which are derived from Tramadol, process for obtaining them and their use for preparing a drug with analgesic properties. These new compounds of general formula (I) have a higher analgesic activity, a lower toxicity and a longer effective time period than Tramadol.